Gregory Delorenzo, MD
Rheumatology · Cincinnati, OHNPI 1508812538
Payments from drug & device makers
Across 3,621 payments — averaging $355.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$446K
- Lilly USA, LLC$188K
- Janssen Scientific Affairs, LLC$154K
- Johnson & Johnson$151K
- Amgen$95K
- UCB, Inc.$61K
- plus $192K from 30 others
What the payments were for
- Consulting fees$114,2419%
- Speaking & faculty fees$985,26477%
- Travel & lodging$134,10610%
- Food & beverage$52,7624%
- Education$1,1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 974 | $445,888 |
| Lilly USA, LLC | 445 | $187,976 |
| Janssen Scientific Affairs, LLC | 131 | $153,590 |
| Johnson & Johnson | 341 | $150,921 |
| Amgen(2 entities) | 494 | $95,407 |
| UCB, Inc. | 438 | $61,418 |
| Novartis | 193 | $58,393 |
| Sanofi | 42 | $39,345 |
| E.r. Squibb & Sons, L.L.C. | 127 | $27,499 |
| Bristol Myers Squibb | 65 | $25,912 |
| Regeneron Healthcare Solutions, Inc. | 66 | $25,884 |
| Pfizer | 103 | $7,014 |
| Eli Lilly | 1 | $2,300 |
| AstraZeneca(2 entities) | 57 | $1,871 |
| Fresenius Kabi USA, LLC | 6 | $1,390 |
| Mallinckrodt Hospital Products Inc. | 31 | $773 |
| Genentech USA, Inc. | 20 | $322 |
| GSK | 24 | $286 |
| Radius Health, Inc. | 14 | $223 |
| ANI Pharmaceuticals, Inc. | 11 | $202 |
| Sanofi-aventis U.S. LLC | 3 | $172 |
| Hikma Pharmaceuticals USA | 11 | $172 |
| Phathom Pharmaceuticals, Inc. | 1 | $126 |
| Organon | 6 | $114 |
| Medexus Pharma, Inc. | 3 | $48 |
| Scilex Pharmaceuticals Inc. | 2 | $34 |
| Sandoz | 2 | $30 |
| Biocon Biologics Inc | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $21 |
| Oxford Immunotec USA Inc | 1 | $20 |
| Sebela Pharmaceuticals Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $15 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,287,476 in reported general payments places this provider in the 95th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 115 | $858,911 |
| RinvoqUpadacitinib | 114 | $744,013 |
| Skyrizi PenRisankizumab-Rzaa | 21 | $436,269 |
| Enbrel SureclickEtanercept | 51 | $382,990 |
| Taltz AutoinjectorIxekizumab | 53 | $346,860 |
| OtezlaApremilast | 67 | $325,409 |
| EnbrelEtanercept | 32 | $233,468 |
| Orencia ClickjectAbatacept | 30 | $185,235 |
| Xeljanz XrTofacitinib Citrate | 30 | $173,185 |
| Humira(Cf)Adalimumab | 24 | $163,123 |
| TremfyaGuselkumab | 11 | $145,770 |
| OfevNintedanib Esylate | 11 | $133,485 |
| OrenciaAbatacept | 17 | $95,516 |
| KevzaraSarilumab | 22 | $93,059 |
| Actemra ActpenTocilizumab | 30 | $64,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $445,888 | $907,136138 claims |
| AmgenOtezla, Enbrel | $95,407 | $558,87799 claims |
| Johnson & JohnsonTremfya | $150,921 | $145,77011 claims |
| Boehringer IngelheimOfev | $15 | $133,48511 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $27,499 | $95,51617 claims |
| SanofiKevzara | $39,345 | $93,05922 claims |
| GSKBenlysta | $286 | $61,94113 claims |
| Medexus Pharma, Inc.Rasuvo | $48 | $14,90426 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $34 | $5,000115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 rheumatology providers in Ohio.
Other rheumatology in Cincinnati
- Michael LuggenCincinnati$1.1M
- Robert HiltzCincinnati$165K
- Michael PordyCincinnati$130K
- David GreenblattCincinnati$121K
- Isam DiabMiddleburg Hts$15.3M
- Sanford WolfeDayton$4.7M
- Jeffrey ChaitoffSolon$3.7M
- Nora SingerCleveland$3M
- Chacko AlappattMiamisburg$2M
- Leonard CalabreseCleveland$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.